HARMONY has been named as a winner of the International Society of Pharmacoeconimics and Outcomes Research (ISPOR) prestigious Best New Investigator Award. The award-winning poster, titled ‘A multilevel evidence access framework for innovative technologies specific to haematological malignancies’ (PCV156), was presented by HARMONY Partner NICE (the National Institute for Health and Care Excellence) at ISPOR Europe 2019, Copenhagen, Denmark.
Lead Researcher and Scientific Advisor at NICE, Dr Katy Harrison, presented the poster, which was one of hundreds showcased at ISPOR and one of 18 final winners.
The poster outlines HARMONY’s new framework, which aims to guide evidence generation to support market access for blood cancer drugs across Europe – a common challenge given the jurisdictional differences across countries. The framework uses information on outcomes of previous reimbursement decisions across European countries to assess the likelihood that a drug is approved based on safety, efficacy, cost and economic requirements by a particular health technology assessment (HTA) body. The framework has the potential to change how HTA submissions are prepared and may prove invaluable for improving the likelihood of approval of such submissions.
The framework will be freely accessible once published.
We would like to thank our Partners at NICE, Celgene International, Janssen-Cilag Germany, AEMPS Spain, BfArM Germany, Abbvie and Novartis UK for their exceptional work on this project.
Receive the latest news. Click here to subscribe!